BPC-157

BPC-157 is a synthetic 15-amino-acid peptide derived from a protein found in human gastric juice. It has remarkable tissue-healing properties in pre-clinical studies — healing gut mucosa, tendons, ligaments, nerves, and muscle. In cancer-care contexts it is used to manage chemotherapy-induced gut toxicity, NSAID damage, and radiation enteritis.

Properties

Amino Acid Sequence

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

Origin: Derived from a protective protein found in human gastric juice

Upregulates growth hormone receptor expression and activates the FAK-paxillin pathway promoting cell survival and migration. Increases VEGF expression for local wound angiogenesis. Modulates the nitric oxide (NO) system bidirectionally — pro-healing locally. Accelerates intestinal anastomosis healing, counteracts NSAID-induced ulceration, and protects the blood-brain barrier.

Primarily used in cancer support (not direct anti-cancer). Key applications: (1) Healing chemotherapy-induced mucositis and gut permeability. (2) Protecting gastric mucosa during NSAID/aspirin use in COC protocols. (3) Counteracting radiation-induced enteritis and proctitis. (4) Accelerating recovery from surgical resections. IMPORTANT: BPC-157 also promotes angiogenesis via VEGF — this is a theoretical concern in active solid tumours and should be discussed with your oncologist.

Links open on PubMed (National Library of Medicine). Research is ongoing — results may not reflect clinical use.

• Promotes angiogenesis (VEGF) — theoretical concern in active solid tumours; discuss with oncologist
• No human clinical trials completed yet; all evidence from animal/cell studies
• Not approved by any regulatory agency; sold as research compound
• Oral form (arginine salt) has much lower bioavailability than injectable
• Source quality varies widely — use reputable peptide suppliers with third-party testing
• Do not use in place of standard mucositis management